Does intra-articular injection of adipose-derived stem cells improve cartilage mass? A case report on a 3D MRI quantitative evaluation of cartilage in knee osteoarthritis using SYNAPSE VINCENT: a case report

Ayano Kuwasawa^{1*}, Kotaro Nihei¹

¹ Saitama cooperative hospital. 1317 Kizoro, Kawaguchi, Saitama, 333-0831, Japan

*Corresponding author

Ayano Kuwasawa, M.D., Ph.D

Saitama cooperative hospital

1317 Kizoro, Kawaguchi, Saitama, 333-0831, Japan

TEL: +81-570-00-4771, FAX: +81-48-296-7182

Abstract:

Background: Mesenchymal stem cells (MSC) are currently in focus because of the possibility of cartilage regeneration through several ways, including MSC sheets. However, there is no published report that visualizes cartilage in three dimensions. Here, we report a case of improved cartilage volume. We purified and cultured adipose-derived mesenchymal stem cells (ASC) and then performed ASC therapy by directly injecting these cells into the articular cartilage. Cartilage was quantitatively evaluated before and after injection using a three-dimensional (3D) image analysis software based on the MRI imagery.

Case presentation: The patient, a 55-year-old woman, experienced pain in both knees and was diagnosed with osteoarthritis of the knee. We performed ASC therapy in both knees at our hospital and quantitatively evaluated cartilage before and after the treatment using the 3D image analysis software “SYNAPSE VINCENT”.

Conclusions: For the quantitative analysis of cartilage, SYNAPSE VINCENT visualizes the state of cartilage in a high-definition 3D image, which is excellent for understanding the state of the disease and explaining it to the patient. Though there is room for debate about the reproducibility of errors, etc., SYNAPSE VINCENT would be useful as a clinical tool for regenerative medicine.

Keywords: Case Report, Knee osteoarthritis, Adipose-derived Stem Cell, Mesenchymal stem cells, Magnetic resonance imaging, Act on issue repair, Quantification of cartilage

Background

Osteoarthritis (OA), which is different from trauma, is a disease that is caused by dysplasia and malalignment. In OA, deterioration and wear of cartilage, which are associated with synovitis, progress over time. The number of patients with OA of the knee in Japan (diagnosed by X-ray) is estimated to be about 25.30 million (8.6 million males and 16.7 million females), and the number of symptomatic patients is estimated to be about 8 million (a large-scale epidemiologic survey ROAD) [1]. In addition, 11% of the main causative diseases requiring care for those aged 65 years or older were caused by joint diseases (Cabinet Office White Paper on Aging Society 2017) [2]. OA reduces the patients' quality of life and daily living activities, leading to the shortening of healthy life expectancy.

According to the guidelines, the optimal management of OA of the knee requires a combination of non-drug therapy and drug therapy [3]. However, regenerative medicine cell therapy, including platelet-rich plasma (PRP) therapy, has recently become widespread and gathered attention as the third type of treatment. As a method of using somatic stem cells, we perform adipose-derived mesenchymal stem cell (ASC) therapy in the hospital, where adipose-derived mesenchymal stem cells (MSCs) are purified, cultured, and injected into the joint. To initiate regenerative medicine using ASCs, a medical institution is required to submit

“a plan for regenerative medicine, etc. based on the article 4, paragraph 1 of the regenerative medicine safety assurance law” to the Ministry of Health, Labour and Welfare in Japan. At our hospital, our application protocol, titled “joint treatment by administration of adipose tissue-derived stem cells”, has received approval since April 2018.

Transplantation of ASCs is one of mesenchymal stromal stem cell-based therapies. This can be performed in two ways: one is a method of extracting and culturing only ASCs for transplantation, called adipose-derived MSC; another is a method of treating adipose tissue with an enzyme to separate a stromal vascular cell group from other fat cells, which is then used for transplantation, called stromal vascular fraction (SVF). Although SVF is not common in Japanese hospitals, a cohort study of patients with knee OA who underwent ASC or SVF showed that there were no serious side effects in both groups and that ASC groups had less adverse events associated with fat collection [4]. This is likely due to the fact that ASCs can be cultured by collecting a small amount of fat with local anesthesia. Additionally, compared to SVF, though it takes longer to prepare (about 6 weeks), ASCs can be cryopreserved. Indeed, the survival rate of ASCs from freeze to thaw is 96.7% when frozen and 83.5% when thawed; thus, more than 80% of stem cells can act in the joint. Moreover, by injecting MSCs, a factor secreted by stem cells affects the environment in the joint and is expected to act on tissue

repair (paracrine effect).

About 20 mL of adipose tissue used for ASC preparation is collected from the patient by a clean operation using a cannula and syringe at Saitama cooperative hospital. The syringe filled with the collected adipose tissue is enclosed in a biohazard bag, packed with a cushioning material, and then shipped to the CellSource Regenerative Medicine Center, a manufacturer of specific cell processed products in Shibuya-ku, Tokyo. After the subculture, ASCs are delivered to our hospital in a frozen state on the day of their scheduled administration and used for the treatment of OA once thawed.

Quantification of cartilage was performed before and after treatment using Fujifilm's 3D image analysis system "SYNAPSE VINCENT," which can convert 2D images produced by an magnetic resonance imaging (MRI) into high-quality 3D images, and used to confirm the adaptation of autologous cartilage jack during the transplantation of ASCs.

This is the first case report of ASC therapy for a patient with knee OA at Saitama cooperative hospital.

Case presentation:

Patient: 55 years old, female

Medical history

In 2013, due to pain in both knees, she visited our hospital and was diagnosed with OA of the knee.

In December 2017, while playing tennis, the right knee developed a knee collapse. She was examined at the hospital, and an MRI of the right knee was performed. Horizontal dissection of the lateral meniscus and cartilage defect on the lateral condyle of the femur were observed.

Since 2018, injection of hyaluronic acid has been continued every 2 weeks, but joint edema and pain recurrence have been remitted.

In April 2018, MRI of the right knee was performed. A cartilage defect was found in the external condyle of the femur, and the patient desired ASC transplantation.

On April 28, 2018, 20 mL ASCs were collected from the abdomen.

On June 11, 2018, the first ASC transplantation was performed on the right knee.

On July 2, 2018, although the effect was experienced after 1 week of treatment, the pain recurred when the subject moved violently.

On August 6, 2018, the patient was in a good condition. When the Timed Up and Go Test was conducted, it showed improvement from 10 seconds to 7 seconds.

On September 10, 2018, the patient was in a good condition. She resumed playing tennis and was living almost without pain.

On December 10, 2018, an MRI was performed. There was no pain even when the subject jumped on one leg and a repaired cartilage defect was observed.

On April 22, 2019, the second ASC transplant was performed on the right knee and the first ASC transplant was performed on the left knee.

On June 22, 2019, there was a slight fever on the day of the procedure.

On August 5, 2019, the patient was in a good condition. It became possible to assume a sitting position.

Results:

Before the operation, the cartilage defect area was 33.59 mm² in the femur and 122.31 mm² in the tibia; however, 6 months after the operation, it improved to 4.59 mm² in the femur, 34.48 mm² in the tibia, and 12 months after the operation, it improved to 13.59 mm² in the femur and 51.43 mm² in the tibia.

The bone volume before the procedure was 9.58 mL for the femur and 3.82 mL for the tibia; however, 6 months after the procedure, it improved to 10.36 mL for the femur and 4.00 mL for the tibia, and 12 months after the procedure, it improved to 10.00 mL for the femur and 4.17 for the tibia (Table 1).

Discussion and Conclusions:

In this case, ASC therapy not only reduced pain but also regenerated the cartilage defect. The side effects were temporary and minor. The reason for the temporary and minor side effects was considered to be the minimal invasion of fat collection and the low burden on the patient.

The reason for regeneration of the cartilage defect area in this case is considered to be that the paracrine effect of the stem cells affected existing surrounding cells in the joint and

repaired cartilage around the defect area. In addition, conditions that enable repair of a cartilage defect include the presence of chondrocytes (a limited defect), a small defect, good alignment, and low mechanical stress.

Although there is a published report stating that a capsule was formed by PRP and stem cell transplantation, there is no published report that states that cartilage regeneration was observed by stem cell transplantation in humans. This case shows an increase in the amount of cartilage by directly injecting MSCs into joints.

It is believed that the results of this study were obtained due to the usefulness of SYNAPSE VINCENT as a diagnostic method, our technical skills, and the culture methods of ASCs. SYNAPSE VINCENT enables the quantitative analysis of cartilage, providing 3D visualization of the state of cartilage in an easy-to-understand manner, which is excellent for understanding the state of the disease and explaining it to the patient. Although there might be room for debate about the reproducibility of errors, etc., SYNAPSE VINCENT would be useful as a clinical tool for regenerative medicine.

Abbreviations

3D: Three-dimensional; ASC: Adipose-derived mesenchymal stem cells; MRI: magnetic resonance imaging; MSC: Mesenchymal stem cells; OA: Osteoarthritis; PRP: platelet-rich plasma; SVF: stromal vascular fraction.

Author's contribution

AK wrote the manuscript. KN reviewed the manuscript and gave suggestions as a supervisor. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

Not applicable

Ethics approval and consent to participate

Ethics approval was obtained from the Saitama cooperative hospital.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Competing interests

The authors declare no competing interests regarding the publication of this article.

Author details

¹ Saitama cooperative hospital

References

[1] Yoshimura N, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T. Cohort Profile: Research on Osteoarthritis/Osteoporosis Against Disability Study. *Int J Epidemiol*. 2010 Aug;39(4):988-995.

[2] Annual Report on the Aging Society, Cabinet Office, Government of Japan (2017).

[3] Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSI Guidelines for the Non-Surgical Management of Knee, Hip, and Polyarticular Osteoarthritis. *Osteoarthritis Cartilage*. 2019 Nov;27:1578-1589.

[4] Yokota N, Hattori M, Ohtsuru T, Otsuji M, Lyman S, Shimomura K, et al. Comparative Clinical Outcomes After Intra-articular Injection With Adipose-Derived Cultured Stem Cells or Noncultured Stromal Vascular Fraction for the Treatment of Knee Osteoarthritis. *Am J Sports Med*. 2019 Sep;47(11):2577-2583.

Table 1. Change of cartilage defect area and cartilage volume

		Before operation	After 6 months	After 12 months
Cartilage defect area (mm)	Femur	33.59	4.59	13.59
	Tibia	122.31	34.48	51.43
Cartilage volume (mL)	Femur	9.58	10.36	10.00
	Tibia	3.82	4.00	4.17

Fig. 1 Clinical course of cartilage area evaluated by MRI (3D image rendered by SYNAPSE VINCENT)

Fig. 2 Clinical course of cartilage thickness evaluated by MRI (3D image rendered by VINCENT)